Table 4.
Clinical pharmacokinetics of oral posaconazole in allogeneic haematopoietic stem cell transplant recipients with GVHD and neutropenic patients receiving chemotherapy for AML or MDS with or without IFI [10, 20]
| Prophylaxis during neutropenia | Prophylaxis during GVHD | |||
|---|---|---|---|---|
| POS (ng ml−1) | Without IFI (n = 188) | With IFI (n = 6) | Without IFI (n = 241) | With IFI (n = 5) |
| Mean Cavg ± SD | 586 ± 379 | 457 ± 169 | 1131 ± 759 | 669 ± 543 |
| Median Cavg (range) | 486 (92–1945) | 454 (254–679) | 922 (0–3650) | 611 (158–1562) |
| Mean Cmax ± SD | 633 ± 413 | 498 ± 194 | 1514 ± 970 | 755 ± 644 |
| Median, Cmax (range) | 531 (92–2400) | 468 (254–781) | 1360 (0–4420) | 635 (158–1800) |
AML, acute myelogenous leukaemia; GVHD, graft-versus-host disease; IFI, invasive fungal infection; MDS, myelodysplastic syndrome; POS, posaconazole.